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Background
Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin–
kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) choles-
terol levels in short-term studies. We conducted two extension studies to obtain 
longer-term data.
Methods
In two open-label, randomized trials, we enrolled 4465 patients who had completed 
1 of 12 phase 2 or 3 studies (“parent trials”) of evolocumab. Regardless of study-
group assignments in the parent trials, eligible patients were randomly assigned in 
a 2:1 ratio to receive either evolocumab (140 mg every 2 weeks or 420 mg monthly) 
plus standard therapy or standard therapy alone. Patients were followed for a me-
dian of 11.1 months with assessment of lipid levels, safety, and (as a prespecified 
exploratory analysis) adjudicated cardiovascular events including death, myocardial 
infarction, unstable angina, coronary revascularization, stroke, transient ischemic 
attack, and heart failure. Data from the two trials were combined.
Results
As compared with standard therapy alone, evolocumab reduced the level of LDL 
cholesterol by 61%, from a median of 120 mg per deciliter to 48 mg per deciliter 
(P<0.001). Most adverse events occurred with similar frequency in the two groups, 
although neurocognitive events were reported more frequently in the evolocumab 
group. The risk of adverse events, including neurocognitive events, did not vary 
significantly according to the achieved level of LDL cholesterol. The rate of cardio-
vascular events at 1 year was reduced from 2.18% in the standard-therapy group to 
0.95% in the evolocumab group (hazard ratio in the evolocumab group, 0.47; 95% 
confidence interval, 0.28 to 0.78; P = 0.003).
Conclusions
During approximately 1 year of therapy, the use of evolocumab plus standard ther-
apy, as compared with standard therapy alone, significantly reduced LDL choles-
terol levels and reduced the incidence of cardiovascular events in a prespecified but 
exploratory analysis. (Funded by Amgen; OSLER-1 and OSLER-2 ClinicalTrials.gov 
numbers, NCT01439880 and NCT01854918.)
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Reduction in low-density lipopro-tein (LDL) cholesterol levels has proved to be highly effective in reducing rates of 
major cardiovascular events in numerous large 
outcome trials.1-3 For this reason, LDL choles-
terol reduction has been incorporated into prac-
tice guidelines as a fundamental means of reduc-
ing cardiovascular morbidity and mortality.4-7
During the past 3 years, monoclonal antibod-
ies that inhibit proprotein convertase subtilisin–
kexin type 9 (PCSK9) have emerged as a new 
class of drugs that very effectively lower LDL 
cholesterol levels.8 One of the members of this 
class is evolocumab, a fully human monoclonal 
antibody that typically achieves approximately a 
60% reduction in LDL cholesterol levels when 
administered at the doses that were studied in 
phase 3 trials.9-13
On completing a trial of evolocumab (parent 
trial), patients could enroll into one of two lon-
ger-term extension trials, designated Open-Label 
Study of Long-Term Evaluation against LDL Cho-
lesterol 1 (OSLER-1), for patients completing 
phase 2 trials, and OSLER-2, for those complet-
ing phase 3 trials. The OSLER-1 and OSLER-2 
trials had as their primary goal the gathering of 
longer-term data on safety, side-effect profile, 
and LDL cholesterol reduction and also included 
a prespecified exploratory analysis on adjudi-
cated cardiovascular outcomes. Here, we report 
on the combined results of the OSLER-1 and 
OSLER-2 trials.
Me thods
Study Design and Oversight
The OSLER-1 trial was an open-label, random-
ized, controlled study conducted at 190 centers 
that participated in at least one of five phase 2 
studies of evolocumab.14-19 Analogously, the OS-
LER-2 trial was an open-label, randomized, con-
trolled study conducted at 305 centers that par-
ticipated in at least one of seven phase 3 studies 
of evolocumab (Table 1).9-13,20,21
The protocols for the OSLER-1 and OSLER-2 
trials were approved by the relevant ethics com-
mittee at each participating site and are available 
with the full text of this article at NEJM.org. 
Amgen sponsored and designed the two trials 
and was responsible for data collection and analy-
sis. The first draft of the manuscript was written 
by the first and last authors. All the coauthors 
participated in subsequent revisions of the man-
uscript. The academic authors had full access to 
the data and vouch for their accuracy and com-
pleteness and for the analyses as presented and 
for the fidelity of this report to the trial proto-
cols. The first and last authors made the decision 
to submit the manuscript for publication.
Patients
There was variation in the clinical characteristics 
of the patients enrolled in the 12 parent studies 
(Table 1). Patients who had completed one of the 
parent studies could enroll in one of the OSLER 
extension studies, provided that they did not have 
an adverse event that led to the discontinuation of 
a study drug during the parent trial, did not have 
an unstable medical condition (in the judgment 
of the investigator), and were not expected to need 
unblinded lipid measurements or adjustment of 
background lipid-regulating therapy during the 
first 12 weeks of participation in the OSLER trials. 
All patients provided written informed consent 
before enrollment in the extension study.
Randomization, Study Treatment,  
and Follow-up
Regardless of the study-group assignment in the 
parent study, eligible patients were randomly as-
signed at the last visit in the parent study, or as soon 
as possible thereafter, to receive either evolocumab 
plus standard therapy (evolocumab group) or stan-
dard therapy alone (standard-therapy group) in 
a 2:1 ratio. Randomization was performed cen-
trally with the use of an interactive voice-response 
or Web-response system, with stratification in 
OSLER-1 according to the study-group assignment 
in the parent trial and in OSLER-2 according to 
the parent trial and study-drug dose frequency 
in the parent trial.
Evolocumab was administered subcutaneously 
at a dose of 420 mg once a month in OSLER-1 
and, on the basis of patient choice, at a dose of 
either 140 mg every 2 weeks or 420 mg once a 
month in OSLER-2. Both regimens have been 
shown to reduce LDL cholesterol levels by approxi-
mately 60% in this patient population.9-13 All pa-
tients, investigators, and care providers were aware 
of the randomized treatment assignments; no 
placebo was used for the standard-therapy group. 
Standard-of-care background therapy in the two 
groups was based on local guidelines for the treat-
ment of LDL cholesterol.
The New England Journal of Medicine 
Downloaded from nejm.org on March 15, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
Evolocumab in Reducing Cardiovascular Events
n engl j med nejm.org 3
To avoid inadvertent unblinding of the parent 
study, lipid results from the central laboratory 
were unblinded only after the week 12 visit in the 
OSLER trials. Adjustments to background lipid-
lowering therapies were discouraged. The study-
visit schedules were similar in OSLER-1 and 
OSLER-2. Common to the two trials, patients were 
to have in-person clinic visits on day 1 and then 
quarterly at weeks 12, 24, 36, and 48. At other time 
points, patients in the evolocumab group had in-
person visits, whereas patients in the standard-
therapy group had telephone contact only.
The trial protocols specified that randomized 
treatment was to conclude at week 56 in OSLER-1 
and at week 48 in OSLER-2. After the end of ran-
domized treatment, all patients were to receive 
open-label evolocumab for longer-term, nonran-
domized assessment of efficacy and safety.
End Points
The primary end point in the two trials was the 
incidence of adverse events. Additional safety end 
points included serious adverse events, adverse 
events leading to the discontinuation of the study 
drug (for patients in the evolocumab group), ab-
normalities in creatine kinase levels and liver-
function testing, and the development of binding 
and neutralizing antibodies against evolocumab, 
which were assayed as reported previously.22
The secondary end point was the percent 
change in the LDL cholesterol level. Other efficacy 
lipid measurements included non–high-density 
lipoprotein (HDL) cholesterol, total cholesterol, 
triglycerides, HDL cholesterol, apolipoproteins A1 
and B, and lipoprotein(a). Lipids were measured 
at a central laboratory (Medpace Reference Labo-
ratories, Cincinnati, and Leuven, Belgium) after 
Table 1. Features of the Parent Trials.*
Trial
No. of Patients  
Enrolled in  
Parent Trial†
No. of Patients  
Enrolled in  
OSLER Trials Patient Population
Phase 2‡
MENDEL-115 406 300 LDL cholesterol level, ≥100 and <190 mg/dl; no background antilipid 
therapy
LAPLACE-TIMI 5714 629 530 LDL cholesterol level, ≥85 mg/dl while receiving statin with or with-
out ezetimibe
GAUSS-117 157 128 Statin-intolerant; LDL cholesterol level, ≥100 mg/dl
RUTHERFORD-116 167 147 Heterozygous familial hypercholesterolemia; LDL cholesterol level, 
≥100 mg/dl while receiving statin with or without  ezetimibe
YUKAWA-119 307 219 High-risk patients in Japan; LDL cholesterol level, ≥116 mg/dl while 
receiving statin
Phase 3§
MENDEL-211 614 378 LDL cholesterol level, ≥100 and <190 mg/dl; no background anti-
lipid therapy
LAPLACE-210 1896 1382 LDL cholesterol level, ≥80 mg/dl (intensive statin at screening), 
≥100 mg/dl (nonintensive statin at screening), or ≥150 mg/dl 
(no statin at screening); moderate- or high-intensity statin with 
or without ezetimibe
GAUSS-212 307 254 Statin-intolerant patients; LDL cholesterol level, ≥100 and <190 mg/dl
RUTHERFORD-213 329 293 Heterozygous familial hypercholesterolemia; LDL cholesterol level, 
≥100 mg/dl while receiving statin with or without ezetimibe
DESCARTES9 901 612 LDL cholesterol level, ≥75 mg/dl while receiving statin with or with-
out ezetimibe
THOMAS-120 149 112 LDL cholesterol level, >85 mg/dl while receiving statin
THOMAS-221 164 110 LDL cholesterol level, >85 mg/dl while receiving statin
*  To convert the values for low-density lipoprotein (LDL) cholesterol to millimoles per liter, multiply by 0.02586.
† Included in this category is the number of patients who underwent randomization and received at least one dose of a study drug.
‡ Patients who were enrolled in phase 2 parent trials and who agreed to participate in the extension study were enrolled in OSLER-1.
§ Patients who were enrolled in phase 3 parent trials and who agreed to participate in the extension study were enrolled in OSLER-2.
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a fast of at least 9 hours. The LDL cholesterol 
level was calculated with the use of the Friede-
wald formula.23
A prespecified exploratory outcome was the 
incidence of adjudicated cardiovascular events, 
which was ascertained over the course of the 
study. (Definitions are provided in the Methods 
section in the Supplementary Appendix, available 
at NEJM.org.) Cardiovascular events included 
death, coronary events (myocardial infarction, 
unstable angina requiring hospitalization, or 
coronary revascularization), cerebrovascular events 
(stroke or transient ischemic attack), and heart 
failure requiring hospitalization. Potential car-
diovascular events were adjudicated by the cen-
tral clinical-events committee at the Thromboly-
sis in Myocardial Infarction (TIMI) Study Group 
in Boston, whose members were unaware of 
treatment assignments. All cardiovascular events 
were combined in an exploratory composite anal-
ysis that was based on the events that were pre-
specified in the trial protocols. In addition, all 
cardiovascular end points except for heart fail-
ure were combined into a post hoc composite of 
major adverse cardiovascular events.
Statistical Analysis
The timing of the analysis in this report was trig-
gered by a planned submission of a biologics li-
cense application to the Food and Drug Admin-
istration. The authors decided to present these 
data to the scientific community at the next ma-
jor scientific meeting. In anticipation of that 
meeting, the data were updated with cardiovas-
cular outcomes that were based on adjudicated 
data through January 21, 2015, along with demo-
graphic, lipid, and safety data that were based on 
cleaned data through October 31, 2014.
The data from the OSLER-1 and OSLER-2 tri-
als were combined into a single analysis set. Data 
for patients were censored at the start of the un-
controlled period in each study. Lipid measure-
ments were summarized with the use of means 
or medians, and treatment differences were test-
ed with the use of the Wilcoxon rank-sum test 
without adjustment for multiplicity. We used the 
Kaplan–Meier method to estimate time-to-event 
cumulative incidence on an intention-to-treat basis. 
Safety was described according to the incidence 
of adverse events. The minimum LDL cholesterol 
category for a patient was determined by the 
minimum value observed in the randomized, con-
trolled period of the studies. We used the log-rank 
test to analyze the difference in cumulative inci-
dence curves for cardiovascular events. Hazard 
ratios were estimated with the use of Cox pro-
portional-hazard models without stratification. 
Statistical analyses were performed with the use 




From October 2011 through June 2014, we en-
rolled a total of 4465 patients in the OSLER pro-
gram (1324 patients in OSLER-1 and 3141 pa-
tients in OSLER-2), which represented 74.1% of 
eligible patients in the parent studies (Table 1). 
Of the 4465 patients, 2976 were randomly as-
signed to receive evolocumab plus standard ther-
apy and 1489 to receive standard therapy alone 
(Fig. S1 in the Supplementary Appendix). The 
median duration of follow-up was 11.1 months 
(interquartile range, 11.0 to 12.8), for a total of 
4219.4 patient-years of follow-up.
The mean age of the patients was 58 years, 
and 80.4% had at least one cardiovascular risk 
factor (Table 2). A total of 3128 patients (70.1%) 
were receiving statin therapy at the start of the 
OSLER trials. Premature permanent discontinu-
ation of evolocumab occurred in 7.2% of pa-
tients. Changes in open-label statin therapy were 
infrequent (for details, see the Results section in 
the Supplementary Appendix).
Lipid Changes
The median baseline LDL cholesterol, before ran-
domization into a parent study, was 120 mg per 
deciliter. At the week 12 visit in the OSLER trials, 
evolocumab, as compared with standard therapy, 
reduced the LDL cholesterol level by 61% (95% 
confidence interval [CI], 59 to 63; P<0.001), for a 
mean absolute reduction of 73 mg per deciliter to 
a median of 48 mg per decileter. Data were simi-
lar in the OSLER-1 and OSLER-2 trials (Table S1 
in the Supplementary Appendix). The reduction 
in LDL cholesterol levels with evolocumab was 
consistent over time (Fig. 1). At 12 weeks, the 
LDL cholesterol level was reduced to 100 mg per 
deciliter or less in 90.2% of patients and to 70 mg 
per deciliter or less in 73.6% of patients in the 
evolocumab group, as compared with 26.0% and 
3.8%, respectively, in the standard-therapy group.
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Mean age ±SD — yr 57.8±11.0 58.2±10.9
Male sex — no. (%) 1490 (50.1) 765 (51.4)
White race — no. (%)† 2559 (86.0) 1267 (85.1)
Region
North America 1402 (47.1) 705 (47.3)
Europe 1205 (40.5) 597 (40.1)
Asia Pacific or South Africa 369 (12.4) 187 (12.6)
Cardiovascular risk factor — no. (%) 2379 (79.9) 1211 (81.3)
Hypertension 1545 (51.9) 777 (52.2)
Diabetes mellitus 382 (12.8) 217 (14.6)
Metabolic syndrome 1035 (34.8) 475 (31.9)
Current cigarette use 465 (15.6) 222 (14.9)
Family history of premature coronary artery disease‡ 724 (24.3) 362 (24.3)
Known familial hypercholesterolemia 289 (9.7) 151 (10.1)
Moderately high risk or high risk on NCEP§ 1332 (44.8) 693 (46.5)
Coronary artery disease — no. (%)
Any 589 (19.8) 307 (20.6)
Myocardial infarction 276 (9.3) 141 (9.5)
Percutaneous coronary intervention 325 (10.9) 170 (11.4)
Coronary-artery bypass grafting 185 (6.2) 110 (7.4)
Cerebrovascular or peripheral-artery disease — no. (%)
Any 266 (8.9) 141 (9.5)
Carotid- or vertebral-artery disease 94 (3.2) 62 (4.2)
Stroke 81 (2.7) 37 (2.5)
Peripheral-artery disease 85 (2.9) 50 (3.4)
Medication use — no. (%)
Statin¶
Any 2073 (69.7) 1055 (70.9)
High-intensity 795 (26.7) 415 (27.9)
Moderate-intensity 1034 (34.7) 522 (35.1)
Low-intensity 240 (8.1) 118 (7.9)
Unknown 4 (0.1) 0
Ezetimibe 376 (12.6) 229 (15.4)
Median lipid measure at baseline in parent study (IQR) — mg/dl
LDL cholesterol 120 (97–148) 121 (97–151)
Total cholesterol  202 (175–234)  205 (174–235)
HDL cholesterol 51 (42–62) 51 (42–62)
Triglycerides 120 (89–165) 119 (89–167)
* Baseline characteristics are based on data that were obtained at the start of the parent study; values for statin use and 
intensity are based on data from the start of the OSLER program. There were no significant differences between the 
two groups at baseline. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. HDL denotes 
high-density lipoprotein, and IQR interquartile range.
† Race was self-reported.
‡ A family history of premature coronary artery disease was defined as the presence of coronary artery disease in a first-
degree male relative 55 years of age or younger or in a first-degree female relative 65 years of age or younger.
§ According to the criteria of the National Cholesterol Education Program (NCEP), moderately high or high risk is de-
fined as coronary heart disease, coronary heart disease equivalent, or two or more cardiovascular risk factors with an 
estimated 10-year risk of cardiovascular events of 10% or more.
¶ The intensity of statin therapy was defined according to recent guidelines.4
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In the evolocumab group, as compared with the 
standard-therapy group, changes in related athero-
genic lipid measures were similar to those ob-
served for LDL cholesterol, with reductions of 
52.0% in non-HDL cholesterol, 47.3% in apolipo-
protein B, 36.1% in total cholesterol, 12.6% in tri-
glycerides, and 25.5% in lipoprotein(a) (P<0.001 
for all comparisons) (Fig. S2 in the Supplementary 
Appendix). Evolocumab raised levels of HDL cho-
lesterol and apolipoprotein A1 by 7.0% and 4.2%, 
respectively (P<0.001 for both comparisons).
Safety and Side-Effect Profile
Adverse events occurred in 2060 of 2976 patients 
(69.2%) in the evolocumab group and in 965 of 
1489 patients (64.8%) in the standard-therapy 
group (Table 3). Serious adverse events occurred in 
222 patients (7.5%) in the evolocumab group and in 
111 patients (7.5%) in the standard-therapy 
group. Elevations in aminotransferase or creatine 
kinase levels occurred at a similar rate in the two 
groups: 1.0% in the evolocumab group and 1.2% in 
the standard-therapy group for elevated amino 
transferase levels and 0.6% and 1.1%, respectively, 
for elevated creatine kinase levels. Although the 
rate of neurocognitive adverse events was low 
(<1%), such events were reported more frequently 
in the evolocumab group. Of note, the incidence 
of neurocognitive adverse events did not appear 
to be related to the LDL cholesterol level during 
treatment (Table S2 in the Supplementary Appen-
dix). Other adverse events are listed in Table S3 in 
the Supplementary Appendix.
Injection-site reactions were reported in 129 
patients (4.3%) in the evolocumab group (the only 
group in which such events were analyzed) and 
led to discontinuation of evolocumab in 6 pa-
tients (0.2%). New evolocumab-binding antibod-
ies were detected in 9 patients (0.3%) in the evo-
locumab group and in 4 patients (0.3%) in the 
standard-therapy group, and binding-antibody 
titers were transient in patients who had repeat 
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Figure 1. Low-Density Lipoprotein (LDL) Cholesterol Levels.
LDL cholesterol was measured in both the OSLER-1 and OSLER-2 trials at 12, 24, and 48 weeks and in the OSLER-1 
trial at 4 and 36 weeks. Shown are median values with 95% confidence intervals in the two studies. Values for the 
baseline measurement were obtained before randomization into a parent study. The dashed lines indicate that pa-
tients were receiving either evolocumab or placebo during the period from baseline to enrollment into OSLER. In 
the chart below the graph, the absolute and percentage reductions in the LDL level in the evolocumab group are 
compared with those in the standard-therapy group and are presented as means. To convert the values for choles-
terol to millimoles per liter, multiply by 0.02586.
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Rates of overall adverse events, serious adverse 
events, and elevations in aminotransferase or cre-
atine kinase levels were similar among patients in 
the evolocumab group who had LDL cholesterol 
levels of less than 40 mg per deciliter or less than 
25 mg per deciliter as in those with higher levels 
during OSLER (Table S2 in the Supplementary Ap-
pendix).
Cardiovascular Events
Cardiovascular events were prospectively adjudicat-
ed in an exploratory analysis (Table S4 in the Sup-
plementary Appendix). When these events were 
combined in a composite of all cardiovascular 
events, patients in the evolocumab group had a sig-
nificantly lower rate of all cardiovascular events 
than did patients in the standard-therapy group 
(Kaplan–Meier estimates at 1 year, 0.95% and 
2.18%, respectively; hazard ratio, 0.47; 95% CI, 0.28 
to 0.78; P = 0.003). The cumulative incidence curves 
diverged progressively over time (Fig. 2). Similar 
results were obtained for the post hoc composite 
of major adverse cardiovascular events (Table S4 
in the Supplementary Appendix).
Discussion
In the OSLER-1 and OSLER-2 trials, open-label 
treatment with evolocumab reduced LDL choles-
terol levels by 61%, from a pretreatment median 
level of 120 mg per deciliter to a 12-week on-
treatment median level of 48 mg per deciliter. 
This result was consistent with reports from pre-
vious short-term trials of evolocumab.9-17,19 In 
the OSLER trials, the reduction in LDL choles-
terol levels was sustained through 48 weeks, a 
finding consistent with the results of a much 
smaller study of evolocumab.9 Effects on other 
lipid fractions were also similar to those seen in 
previous studies.
Some nonspecific adverse events (arthralgia, 
headache, limb pain, and fatigue) and neurocog-
nitive adverse events were reported more fre-
quently in the evolocumab group than in the 








Any 2060 (69.2) 965 (64.8)
Serious 222 (7.5) 111 (7.5)
Leading to discontinuation of evolocumab 71 (2.4) NA
Muscle-related 190 (6.4) 90 (6.0)
Injection-site reaction 129 (4.3) NA
Neurocognitive event† 27 (0.9) 4 (0.3)
Other‡
Arthralgia 137 (4.6) 48 (3.2)
Headache 106 (3.6) 32 (2.1)
Limb pain 99 (3.3) 32 (2.1)
Fatigue 83 (2.8) 15 (1.0)
Laboratory results
Alanine or aspartate aminotransferase >3 × ULN at any visit after 
baseline
31 (1.0) 18 (1.2)
Creatine kinase >5 × ULN at any visit after baseline 17 (0.6) 17 (1.1)
* NA denotes not applicable, and ULN upper limit of the normal range.
† Neurocognitive events were delirium (including confusion), cognitive and attention disorders and disturbances, dementia 
and amnestic conditions, disturbances in thinking and perception, and mental impairment disorders.
‡ Included in this category are adverse events that were reported in at least 1% of patients in the evolocumab group and 
in more patients in the evolocumab group than in the standard-therapy group by at least 1 percentage point.
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standard-therapy group. These observations 
should be viewed in the context of the greater 
number of protocol-stipulated in-person visits 
for patients in the evolocumab group as well as 
the open-label nature of the trial, which could 
predispose patients who are receiving the study 
intervention to be more likely to note adverse 
events, particularly those associated with other 
therapies that reduce LDL cholesterol.24 More-
over, there did not appear to be any excess of 
these events in patients who had very low versus 
higher on-treatment levels of LDL cholesterol. 
Furthermore, PCSK9 loss-of-function variants 
have not been associated with impaired cognitive 
performance.25 Nonetheless, much larger trials, 
including a dedicated neurocognitive substudy 
(ClinicalTrials.gov number, NCT02207634),26 are 
ongoing to provide more definitive assessments 
of safety over longer-term follow-up.
An unanswered question is whether a reduc-
tion in the LDL cholesterol level with a PCSK9 
inhibitor will lead to a reduction in cardiovascu-
lar events. Reduction in such events with statins 
has been well established during the past two 
decades in numerous large, randomized, con-
trolled trials.1,2 In contrast, it has been difficult 
to show that adding other lipid-modifying drugs 
to statins results in a further decrease in cardio-
vascular events, which is probably due to the 
modest effects on LDL cholesterol or off-target 
adverse effects.27-30 This issue was a factor con-
tributing to the most recent set of practice guide-
lines from the American College of Cardiology–
American Heart Association, in which the role 
of nonstatin lipid-modifying drugs was dimin-
ished, as compared with previous guidelines.4 
Recently, however, in the Improved Reduction of 
Outcomes: Vytorin Efficacy International Trial 
(IMPROVE-IT), an additional reduction in LDL 
cholesterol levels with the addition of ezetimibe, 
a cholesterol-absorption inhibitor, to a statin sig-
nificantly reduced cardiovascular events, as com-
pared with statin monotherapy.3 These data have 
refocused attention on the potential cardiovas-
cular benefit of greater LDL cholesterol reduc-
tion through nonstatin mechanisms.
Evolocumab, unlike other nonstatin lipid-
modifying drugs, reduces LDL cholesterol levels 
as much as, if not more than, high doses of 
statins. Also, PCSK9 inhibitors have the same 
ultimate mechanism for LDL reduction as statins 
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Figure 2. Cumulative Incidence of Cardiovascular Events.
Included among the cardiovascular events were death, myocardial infarction, unstable angina requiring hospitaliza-
tion, coronary revascularization, stroke, transient ischemic attack, and hospitalization for heart failure. Cardiovascu-
lar events were reported in 29 of 2976 patients in the evolocumab group (Kaplan–Meier 1-year event rate, 0.95%) 
and in 31 of 1489 patients in the standard-therapy group (Kaplan–Meier 1-year event rate, 2.18%). The inset shows 
the same data on an expanded y axis. The P value was calculated with the use of a log-rank test.
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the hepatocyte surface,8 suggesting that PCSK9 
inhibitors should similarly have a beneficial ef-
fect on cardiovascular outcomes. Additional sup-
port for the potential of PCSK9 inhibition in 
reducing cardiovascular events comes from the 
observation that loss-of-function genetic vari-
ants leading to reductions in PCSK9 activity have 
been associated with significantly lower lifetime 
rates of cardiovascular events.31 Thus, the reduc-
tion in cardiovascular events seen in the OSLER 
trials within the first year of evolocumab thera-
py, even though the analysis was both explor-
atory and based on a relatively small number of 
events, is consistent with the large reduction in 
LDL cholesterol levels, the mechanism of action, 
and the PCSK9 genetic data.
The Further Cardiovascular Outcomes Re-
search with PCSK9 Inhibition in Subjects with 
Elevated Risk (FOURIER) study (NCT01764633) 
is an ongoing trial that is intended to provide a 
definitive assessment of the cardiovascular ben-
efit of evolocumab. The FOURIER study is a 
randomized, placebo-controlled trial involving 
27,500 high-risk patients with cardiovascular 
disease who are receiving background statin 
therapy; the primary end point is a composite of 
cardiovascular death, myocardial infarction, hospi-
talization for unstable angina, stroke, or coronary 
revascularization.32 Similar trials of alirocumab 
and bococizumab to evaluate cardiovascular 
outcomes are in progress (NCT01663402, 
NCT01975376, and NCT01975389).33-35
Several study limitations are noteworthy. First, 
the open-label design of the trials could have had 
an influence on the reporting of events, both 
cardiovascular and safety. This issue would es-
pecially be a concern for coronary revasculariza-
tion, the single most frequently reported cardio-
vascular event, since the decision to perform this 
procedure could have been influenced by knowl-
edge of treatment assignment. Second, the num-
bers of cardiovascular and select adverse events 
were relatively small. Third, although rates of ad-
verse events and study-drug discontinuation were 
low in the parent trials,9-17,19 patients were eli-
gible to transition to the OSLER trials if they had 
not had an adverse event that led to the discon-
tinuation of a study drug. Thus, data on safety 
and side-effect profiles in our study come from 
a cohort of patients who had all successfully 
received injections and many of whom had re-
ceived evolocumab for at least 12 weeks. Fourth, 
the OSLER program included a mix of patients 
with varying degrees of cardiovascular risk and 
use and intensity of statin therapy. Thus, not all 
the study patients would necessarily have been the 
optimal target population for this novel treatment.
In conclusion, patients who had previously 
participated in 12 shorter-term parent trials of 
the PCSK9 inhibitor evolocumab underwent 
repeat randomization to receive either evo-
locumab or standard therapy in the OSLER 
program. Evolucumab reduced levels of LDL 
cholesterol by 61% by 12 weeks, with sustained 
reduction through the median 11-month fol-
low-up. In a prespecified exploratory analysis, 
there was evidence of a reduction in the rate of 
cardiovascular events among patients receiving 
evolocumab.
Supported by Amgen.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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